Related Experiment Video
Updated: Jun 18, 2026

HSV-Mediated Transgene Expression of Chimeric Constructs to Study Behavioral Function of GPCR Heteromers in Mice
Published on: July 9, 2016
Antipsychotic medication: the potential role of 5-HT(1A) receptor agonism
Andrew C McCreary1, Caitlin A Jones
1Solvay Pharmaceuticals Research Laboratories, van Houtenlaan 36, 1381 CP, Weesp, The Netherlands. andrew.mccreary@solvay.com
Abstract:
Schizophrenia is a complex psychiatric disorder characterised by positive and negative symptoms, cognitive impairments, attentional problems, anxiety and depressive symptoms. The use of atypical antipsychotics has generally improved clinical outcome yet medical need remains in the treatment of this disease. The potential use of 5-HT(1A) receptor agonism is emerging as one potential area that could be exploited to improve clinical management of the disease. 5-HT(1A) receptor agonism will not reduce hyperprolactinaemia but does appear to enhance effects on positive, negative and cognitive symptoms and also treat attentional depressive and anxiety symptoms. However, these improvements are not at the expense extrapyramidal side effects and indeed may attenuate the effects of D(2) receptor antagonism. Agonism at the 5-HT(1A) receptor might therefore offer potential benefits to the pallet of existing strategies for the treatment of schizophrenia. We review existing data in support of this. However, further clinical data are needed to prove these hypotheses.
Related Concept Videos
Antipsychotic Drugs: Typical and Atypical Agents
Antipsychotic Drugs: Therapeutic Uses and Side Effects
Despite these side effects, antipsychotics are used therapeutically for various purposes, including managing schizophrenia, preventing nausea and vomiting, curbing...
Psychosis and Antipsychotic Drugs: Overview
Psychosis: Goals of Pharmacotherapy
Drug Therapy
Antianxiety Medications
Antidepressant Drugs: MAOIs and Other Agents
